Preclinical CRO strengthens leadership team with key executive appointments as it scales its human tissue-based drug discovery platform
At 34 weeks, Ultomiris achieved a 43.4% placebo-adjusted reduction in 24-hour urine protein creatinine ratio (UPCR) versus placebo, meeting the study’s key interim endpoint
The campaign places renewed focus on a disease that remains incurable despite major scientific advances
The company said Wegovy hit its first one million prescriptions within 12 weeks of availability
The company said data from multiple VESPER studies show the peptide delivered meaningful weight loss, favorable tolerability, and the possibility of a first-in-class monthly injection format
The launch comes against the backdrop of a significant public health burden
Broadening access for children & patients with inhibitor-complicated hemophilia
Investigational once-weekly GLP-1 and amylin receptor agonist achieves up to 14.6% weight loss and significant blood sugar reductions
The drug currently approved for chronic kidney disease (CKD) associated with type 2 diabetes, may benefit a much broader group of patients than previously recognized
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
